Key result
High circulating levels of ET-1, big ET-1, and CT-proET-1 were associated with increased risk of adverse outcomes in heart failure patients.
Why the study?
Are high plasma levels of ET-1, big ET-1, and CT-proET-1 associated with poor prognosis and mortality in patients with heart failure?
Meta-Analysis (n=18,497)
Are high plasma levels of ET-1, big ET-1, and CT-proET-1 associated with poor prognosis and mortality in patients with heart failure?
Increased plasma levels of ET-1, big ET-1, and CT-proET-1 are significantly associated with poor prognosis and higher mortality in patients with heart failure.
Answers are grounded in this paper and cite their sources.
May aid HF risk stratification; reinforces prognostic value of ET-1 markers but leaves therapeutic implications open.
BACKGROUND: Most studies reported that high plasma endothelin-1 (ET-1), big ET-1, and C-terminal proET-1 (CT-proET-1) were correlated with poor prognosis of heart failure (HF). However, available evidence remains controversial. To help solve the debate, we collected all the available studies and performed a meta-analysis. METHODS: We searched the databases covering Embase, PubMed, Ovid, and Web of Science on June 28, 2017. The hazard ratio (HR) or risk ratio (RR) and its 95% confidence intervals (CIs) were collected and calculated by use of a random-effect model. Heterogeneity was assessed by Cochran's Q test, and publication bias was assessed by funnel plots with Egger's and Begg's linear regression test. RESULTS: Thirty-two studies with 18,497 patients were included in the analysis. Results showed that circulating ET-1, big ET-1, and CT-proET-1 were positively correlated with high risk of adverse outcomes, with pooled RRs (95% CIs) of 2.22 (1.82-2.71, P < .001), 2.47 (1.93-3.17, P < .001), and 2.27 (1.57-3.29, P < .001), respectively. In the subgroup of death as primary outcome, the pooled RRs (95% CIs) were 2.13 (1.68-2.70, P < .001), 2.55 (1.82-3.57, P < .001), and 2.02 (1.39-2.92, P < .001) for ET-1, big ET-1, and CT-proET-1, respectively. No significant publication bias was observed in this study. CONCLUSION: Our meta-analysis provided evidence that increased plasma levels of ET-1, big ET-1, and CT-proET-1 were associated with poor prognosis or mortality for HF populations.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2017) conducted a meta-analysis in Heart failure (n=18,497). High plasma endothelin-1 (ET-1) vs. Low plasma endothelin-1 (ET-1) was evaluated on Adverse outcomes (death, heart transplant, or HF hospitalization) (RR 2.22, 95% CI 1.82-2.71, p=<0.001). High circulating levels of ET-1, big ET-1, and CT-proET-1 were associated with increased risk of adverse outcomes in heart failure patients.
Synapse has enriched 10 related papers. Consider them for comparative context: